NEW YORK (GenomeWeb News) – Agilent Technologies said after the close of the market on Monday that revenues for its Fiscal Year 2012 fourth quarter increased 2 percent year over year.

Total revenues for the three months ended Oct. 31 rose to $1.77 billion from $1.73 billion a year ago, edging out the average analyst estimate of $1.76 billion. Orders during the quarter were flat at $1.75 million.

"The headline for this quarter is that most of our end markets remained soft," Agilent CEO Bill Sullivan said on a conference call after the release of the company's earnings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.